MO38-3 Clinical update with genomic analyses in expansion part of phase 1 study of selective FGFR inhibitor E7090

Abstract

The first-in-human phase I study of E7090 consists of dose-escalation (Part 1) and expansion (Part 2) part, which has been conducted in Japan. In Part 2, we analyzed tumor tissues and plasma samples with NGS panels to assess baseline tumor gene characteristics and evolution of the ctDNA profile during E7090 treatment.